Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085107 | 0.85 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL961222 | 0.81 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL964815 | 0.81 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5689033 | 0.78 | LMNA (0.33) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL1133839 | 0.78 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL23357664 | 0.77 | NAAA (0.41) | LMNAUSP2KDM4E | |
| SCHEMBL4850735 | 0.76 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5173596 | 0.76 | PDE4A (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL31083827 | 0.75 | PDE4A (0.52) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3862937 | 0.75 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-4014987-A2 | CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | Igisu Co., Ltd. (JP) | 2022-06-22 | — | — | EP | disclosed |
| US-20210277062-A9 | CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | IGISU CO., LTD. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20200347096-A1 | CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | IGISU CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3305804-A1 | CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | Igisu Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20180066020-A1 | A CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | IGISU CO., LTD. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-6497889-B2 | CONTAINING HYDROXYPROLINE COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-20020009472-A1 | Cosmetics | KYOWA HAKKO BIO CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-1166767-A2 | Skin care product containing hydroxyproline or N-acylated hydroxyproline derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347096-A1 | CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | TSLP, NPR1, VIP | LMNA 4657/4885L3MBTL1 4810/4885PDE4A 688/4885 |
| US-20180066020-A1 | A CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | NPR1, TSLP, FGF1 | LMNA 4600/4885L3MBTL1 4822/4885PDE4A 646/4885 |
| US-20210277062-A9 | CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | TSLP, NPR1, VIP | LMNA 4657/4885L3MBTL1 4810/4885PDE4A 688/4885 |
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | LMNA 4657/4885L3MBTL1 4810/4885PDE4A 688/4885 |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | LMNA 4657/4885L3MBTL1 4810/4885PDE4A 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.